中文摘要：
巨噬細胞具有多種功能，包括免疫調節、形態發生、組織穩態和愈合反應。目前的觀點認為，乳腺巨噬細胞在青春期前期出生后出現，來源于骨髓衍生的單核細胞。在此，我們通過高維表型分析、細胞命運追蹤實驗、缺失特定巨噬細胞亞型的基因缺陷小鼠以及基于抗體的消耗策略，闡明了組織駐留乳腺巨噬細胞的起源。我們發現，組織駐留巨噬細胞在出生前便存在于乳腺中，而且卵黃囊來源和胎肝來源的巨噬細胞在成年乳腺中數量仍多于成人來源的巨噬細胞。此外，胎兒來源的乳腺巨噬細胞具有特征性表型，顯示出偏向導管周圍和血管周圍的定位，并在清除功能上非常活躍。這些發現將胎兒來源的巨噬細胞確定為成年乳腺基質中主要的白細胞類型，并揭示了乳腺巨噬細胞生物學此前未知的復雜性。
英文摘要：
Macrophages serve multiple functions including immune regulation, morphogenesis, tissue homeostasis and healing reactions. The current paradigm holds that mammary gland macrophages first arise postnatally during the prepubertal period from the bone marrow-derived monocytes. Here we delineate the origins of tissue-resident mammary gland macrophages using high-dimension phenotypic analyses, cell-fate mapping experiments, gene-deficient mice lacking selective macrophage subtypes, and antibody-based depletion strategies. We show that tissue-resident macrophages are found in mammary glands already before birth, and that the yolk sac-derived and fetal liver-derived macrophages outnumber the adult-derived macrophages in the mammary gland also in the adulthood. In addition, fetal-derived mammary gland macrophages have a characteristic phenotype, display preferential periductal and perivascular localization, and are highly active in scavenging. These findings identify fetal-derived macrophages as the predominant leukocyte type in the adult mammary gland stroma, and reveal previously unknown complexity of macrophage biology in the breast.
論文信息：
論文題目：Fetal-derived macrophages dominate in adult mammary glands
期刊名稱：Nature Communications
時間期卷：10, Article number: 281(2019)
在線時間：2019年1月17日
DOI： doi.org/10.1038/s41467-018-08065-1
產品信息：
貨號：CP-005-005
規格：5ml+5ml
品牌：Liposoma
產地：荷蘭
名稱：Clodronate Liposomes&Control liposomes
辦事處：Target Technology(靶點科技)
Clodronate Liposomes氯膦酸鹽脂質體聯合抗體清除外周和乳腺定居巨噬細胞 ，荷蘭Liposoma巨噬細胞清除劑ClodronateLiposomes見刊于Nature Communications：胎源性巨噬細胞在成年乳腺中占主導地位。
Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質體清除乳腺巨噬細胞的材料和方法：
To deplete YS-derived macrophages pregnant female mice were treated with a single injection of CSF-1R blocking antibody (clone AFS98, Bio X Cell) or rat IgG2a control antibody (clone 2A3, Bio X Cell). Three mg of the antibodies in sterile PBS were administered i.p. to pregnant females at E6.5, as described12,32. Mice were sacrificed at E17.5 or at postnatal age of 2 wk or 5 wk for flow cytometric analyses.
To deplete tissue-resident macrophages after birth, 2 wk old C57Bl/6N mice were cyclically treated with anti-CSF1 antibody and clodronate (Fig. 2b). To that end, three doses of CSF1 neutralizing antibody (Clone 5A1, BioXcell) or control IgG (clone HRPN, BioXcell) were given i.p. (0.5?mg on postnatal day 14, 0.25?mg on postnatal day 18 and 0.25?mg on postnatal day 22). On subsequent days, three doses of clodronate or control liposomes (Liposoma) 50?µl/injection on postnatal days 15, 19 and 23) were administered i.v. The mice were sacrificed 1 or 11 days after the final clodronate treatment. In control experiments using kidney, we saw a full recovery of a known bone marrow-derived CD11b+F4/80Int macrophage population, but not that of a known fetal-derived CD11bIntF4/80Hi macrophage population, verifying the robustness of the model.
材料和方法文獻截圖：
